This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Guardion Health Sciences Crescita futura

Future criteri di controllo 1/6

Si prevede che Guardion Health Sciences aumenterà gli utili e i ricavi rispettivamente del 35.8% e 12.5% all'anno, mentre si prevede che l'EPS crescerà del 47.6% all'anno.

Informazioni chiave

35.8%

Tasso di crescita degli utili

47.6%

Tasso di crescita dell'EPS

Personal Products crescita degli utili	7.8%
Tasso di crescita dei ricavi	12.5%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	22 Feb 2023

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:0QTA - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	14	-7	N/A	N/A	1
12/31/2023	12	-8	N/A	N/A	1
12/31/2022	11	-8	N/A	N/A	1
9/30/2022	11	-21	-8	-8	N/A
6/30/2022	11	-22	-8	-8	N/A
3/31/2022	9	-25	-11	-10	N/A
12/31/2021	7	-25	-11	-11	N/A
9/30/2021	5	-14	-11	-11	N/A
6/30/2021	2	-13	-11	-11	N/A
3/31/2021	2	-9	-9	-9	N/A
12/31/2020	2	-9	-8	-8	N/A
9/30/2020	2	-9	-8	-8	N/A
6/30/2020	2	-9	-8	-8	N/A
3/31/2020	1	-12	-7	-7	N/A
12/31/2019	1	-11	-6	-6	N/A
9/30/2019	1	-8	-5	-5	N/A
6/30/2019	1	-8	-4	-4	N/A
3/31/2019	1	-7	-4	-3	N/A
12/31/2018	1	-8	-4	-4	N/A
9/30/2018	1	-9	-5	-5	N/A
6/30/2018	1	-9	-5	-5	N/A
3/31/2018	1	-8	-4	-4	N/A
12/31/2017	0	-6	-3	-3	N/A
9/30/2017	0	-6	-2	-2	N/A
6/30/2017	0	-6	-2	-2	N/A
3/31/2017	0	-6	-2	-2	N/A
12/31/2016	0	-7	-2	-2	N/A
9/30/2016	0	-5	-2	-2	N/A
6/30/2016	0	-6	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che 0QTA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che 0QTA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che 0QTA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di 0QTA ( 12.5% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 0QTA ( 12.5% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 0QTA è previsto essere elevato tra 3 anni

This company listing is no longer active

Guardion Health Sciences Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Guardion Health Sciences' Common Stock to be Deleted from OTC Equity

Guardion Health Sciences Expects the Official Delisting of its Common Stock to be Effective October 21, 2024

Guardion Health Sciences, Inc. Appoints Mark Goldstone as Interim Chief Executive Officer, Effective as of October 18, 2024

Guardion Health Sciences, Inc. Declares Dividend, Payable on September 23, 2024

Doctor's Best, Inc. agreed to acquire Activ Nutritional, LLC. from Guardion Health Sciences, Inc. (NasdaqCM:GHSI) for $17.2 million.

Guardion Health Sciences, Inc., Annual General Meeting, Nov 21, 2023

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences, Inc. Announces Executive Changes

Guardion Health Sciences Regains Compliance with Nasdaq Continued Listing Requirements

Guardion Health Sciences, Inc. Announces Clinical Results Indicating that Viactiv® Omega Boost™ Gel Bites Increase Omega-3 Levels in Just 4 weeks

Guardion Health Sciences, Inc., Annual General Meeting, Jun 16, 2022

Guardion Health Sciences, Inc. Announces New Viactiv® Omega Boost Gel Bites Now Available for Purchase Via Viactiv® Shopify Store

Guardion Health Sciences, Inc. Launches New Viactiv® Omega BOOST™ Passion Fruit Flavored Gel Bites

Guardion Health Sciences to Wind Down VectorVision Business Operations and Focus on Exploiting VectorVision Intellectual Property

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) completed the acquisition of Activ Nutritional, LLC from Adare Pharmaceuticals, Inc.

Guardion Health Sciences, Inc. (NasdaqCM:GHSI) entered into an Equity Purchase Agreement to acquire Activ Nutritional, LLC from Adare Pharmaceuticals, Inc. for $26 million.

Guardion Health Sciences, Inc. Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Guardion Health Sciences Regains Compliance with Nasdaq Minimum Bid Price Rule

Guardion Health Sciences Announces 1-For-6 Reverse Stock Split to Comply with the $1.00 Per Share Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

New 90-day high: €1.06

Guardion Health Sciences Receives Regulatory Product Registration Approval for Second Immune Support Dietary Supplement Designed and Produced by Guardion Health Sciences

Nasdaq Grants Guardion Health Sciences an Extension to March 15, 2021 to Regain Compliance with the $1.00 Minimum Bid Price Rule

New 90-day high: €0.77

HO WAH GENTING BERHAD Appoints Guardion Health Sciences, Inc to Design and Manufacture an Exclusive Custom Immune Support Nutraceutical Formula

Guardion Health Sciences, Inc. Appoints Bret Scholtes as Chief Executive Officer Commencing January 6, 2021

New 90-day high: €0.26

Guardion Health Sciences Announces Development of New Vision/Energy Support Drink – EPIQ-V

New 90-day high: €0.23

Third quarter 2020 earnings released: US$0.024 loss per share

Guardion Health Sciences Announces Investigator-Initiated Clinical Trial of Lumega-Z

New 90-day low - €0.23

First half earnings released

Guardion Health Sciences, Inc. to Report Q2, 2020 Results on Aug 12, 2020

New 90-day low - €0.34

New 90-day low - €0.35

Guardion Health Sciences, Inc.(NasdaqCM:GHSI) dropped from Russell Microcap Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita